EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access · CC BY 4.0

Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel

Jaden Brandt iD, Nicole Lamberson, Jolene Bressi, Alexis Ritvo, Janice Curle, Josef Witt-Doerring, Marjorie DeWert, Steven Wright, Mark Horowitz iD

Therapeutic Advances in Psychopharmacology · 2026-06 · 16

DOI: 10.1177/20451253261457547 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 09.06.2026. Verfasst von Jaden Brandt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Alliance for Benzodiazepine Best Practices, Portland, OR, USA. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benzodiazepine receptor agonists (BZRA) are frequently tapered because of risk of dependence and hazards of use in ageing. Standard tapering protocols may fail or result in harm from improper utilization of pharmacologic principles, lack of recognition of withdrawal and/or failures in shared decision-making.

Objective

The aim of this work was to derive principles from experts to optimize deprescribing success while minimizing withdrawal among patients who use BZRA medication long-term.

Design

Modified Delphi consensus study among experts from two not-for-profit organizations dedicated to BZRA use issues.

Methods

Three stages of anonymized voting were conducted among clinical experts and patient representatives. An 80% agreement (‘agree’ or ‘strongly agree’ on a five item Likert-type scale) was required for consensus. Recommendations which failed to reach initial consensus, were modified from feedback and downgraded to ‘moderate’ (>80% agreement) or ‘weak’ consensus (50%–80% agreement) in the subsequent rounds.

Results

A total of 35 of 48 invitees participated (73% response rate) which included seven family physicians, nine psychiatrists, five pharmacists, six patient advocates, two nurse practitioners, two licensed clinical social workers, two health service policy researchers, a physician assistant and a psychotherapist. A total of 31 of 35 participants were from the United States, with the remaining representatives from Canada, the UK and Ireland. Strong consensus was achieved for attaining informed consent prior to deprescribing (recommendation 1), using a flexible and gradual tapering approach (recommendation 2) characterized by shared decision-making (recommendation 3) with hyperbolic dose reductions (recommendation 4) facilitated via novel preparation techniques or compounded pharmaceutical formulations (recommendation 7). Reversion to previous doses may occur if necessary to reduce the incidence of withdrawal (recommendation 6). Strong consensus was also reached for adjunctive psychosocial interventions (recommendation 8) and/or peer-support resources (recommendation 9). Moderate and weak consensus was achieved, respectively, for step-wise conversion to a longer-acting BZRA (recommendation 5) and the avoidance of adjunctive non-BZRA pharmacotherapy (recommendation 10).

Conclusion

This consensus guidance document for primary care providers, mental health clinicians and long-term users of BZRA outlines ten principles/recommendations intended for improving deprescribing outcomes with an emphasis on minimizing withdrawal risk.

Schlagwörter

Stichwörter der Autor:innen

benzodiazepinedependencedeprescribingtaperingwithdrawal

Autor:innen und Institutionen

  • Alliance for Benzodiazepine Best Practices, Portland, OR, USA.
  • College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Ave., Winnipeg, MB R3E 0T5, Canada.
  • Benzodiazepine Information Coalition, Venice, FL, USA.
  • School of Public Health, Yale University, New Haven, CT, USA.
  • Psychiatry, University of Colorado Anschutz, Anschutz Medical Campus, Aurora, CO, USA.
  • North East London NHS Foundation Trust, Research and Development, London, UK.

ORCID-Profile: Jaden Brandt, Mark Horowitz

Zitieren

APA

Brandt, J., Lamberson, N., Bressi, J., Ritvo, A., Curle, J., Witt-Doerring, J., DeWert, M., Wright, S., & Horowitz, M. (2026). Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261457547

Vancouver

Brandt J, Lamberson N, Bressi J, Ritvo A, Curle J, Witt-Doerring J, et al. Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261457547

BibTeX
@article{Brandt2026,
  author = {Brandt, Jaden and Lamberson, Nicole and Bressi, Jolene and Ritvo, Alexis and Curle, Janice and Witt-Doerring, Josef and DeWert, Marjorie and Wright, Steven and Horowitz, Mark},
  title = {Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2026},
  volume = {16},
  doi = {10.1177/20451253261457547}
}
Kostenlos starten →